Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Dormant

Current status date:

2020-08-31

Original market date: See footnote 1

1998-03-09

Product name:

TRIANAL C½

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

01971387

Product Monograph/Veterinary Labelling:

Date: 2018-10-22 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville
Quebec
Canada J7C 3V4

Class:

Human

Dosage form(s):

Capsule

Route(s) of administration:

Oral

Number of active ingredient(s):

4

Schedule(s):

Narcotic (CDSA I)

 

American Hospital Formulary Service (AHFS): See footnote 3

28:08.08  ,  28:08.04.24 

Anatomical Therapeutic Chemical (ATC): See footnote 4

N02AA79 CODEIN, COMBINATIONS WITH PSYCHOLEPTICS

Active ingredient group (AIG) number:See footnote5

0401238001

List of active ingredient(s)
Active ingredient(s) Strength
ACETYLSALICYLIC ACID 330 MG
BUTALBITAL 50 MG
CAFFEINE 40 MG
CODEINE PHOSPHATE 30 MG

Risk Management Plans See footnote 7

A Canadian Specific Opioid targeted Risk Management Plan (CSO-tRMP) for this product was submitted.

Additional Risk Minimization Measures
Healthcare Professional Education
Version 4.0.2
Date modified: